share_log

Don't Ignore The Insider Selling In TG Therapeutics

Don't Ignore The Insider Selling In TG Therapeutics

不要忽視TG Therapeutics內部人士的減持
Simply Wall St ·  11/09 09:33

We'd be surprised if TG Therapeutics, Inc. (NASDAQ:TGTX) shareholders haven't noticed that the Independent Director, Yann Echelard, recently sold US$490k worth of stock at US$24.48 per share. On the bright side, that sale was only 8.2% of their holding, so we doubt it's very meaningful, on its own.

如果TG Therapeutics, Inc.(納斯達克股票代碼:TGTX)的股東沒有注意到獨立董事亞恩·埃切拉德最近以每股24.48美元的價格出售了價值49萬美元的股票,我們會感到驚訝。好的一面是,那次出售僅佔他們持股量的8.2%,因此我們懷疑這本身是否有意義。

The Last 12 Months Of Insider Transactions At TG Therapeutics

TG Therapeutics 過去 12 個月的內幕交易

Over the last year, we can see that the biggest insider sale was by the CFO, Corporate Secretary & Treasurer, Sean Power, for US$809k worth of shares, at about US$16.91 per share. That means that an insider was selling shares at slightly below the current price (US$28.81). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. It is worth noting that this sale was only 6.6% of Sean Power's holding.

在過去的一年中,我們可以看到,最大的內幕出售是首席財務官、公司秘書兼財務主管肖恩·鮑爾,以每股約16.91美元的價格出售了價值80.9萬美元的股票。這意味着一位內部人士正在以略低於當前價格(28.81美元)的價格出售股票。通常,當內部人士以低於當前價格的價格出售時,我們認爲這令人沮喪,因爲這表明他們對較低的估值感到滿意。但是,請注意,賣家可能有各種各樣的賣出原因,因此我們不確定他們對股價的看法。值得注意的是,此次出售僅佔肖恩·鮑爾持股的6.6%。

TG Therapeutics insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

去年,TG Therapeutics內部人士沒有購買任何股票。下圖顯示了去年的內幕交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!

big
NasdaqCM:TGTX Insider Trading Volume November 9th 2024
納斯達克股票代碼:TGTX 內幕交易量 2024 年 11 月 9 日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

如果你喜歡買入內部人士正在買入的股票,而不是賣出,那麼你可能會喜歡這份免費的公司名單。(提示:它們中的大多數都在雷達下飛行)。

Insider Ownership

內部所有權

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. TG Therapeutics insiders own 7.0% of the company, currently worth about US$278m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。我認爲,如果內部人士擁有該公司的大量股份,這是一個好兆頭。TG Therapeutics內部人士擁有該公司7.0%的股份,根據最近的股價,目前價值約2.78億美元。我喜歡看到這種程度的內部所有權,因爲它增加了管理層考慮股東最大利益的機會。

So What Does This Data Suggest About TG Therapeutics Insiders?

那麼這些數據對TG Therapeutics Insiders有何啓示呢?

An insider hasn't bought TG Therapeutics stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing TG Therapeutics. Every company has risks, and we've spotted 1 warning sign for TG Therapeutics you should know about.

在過去的三個月中,一位內部人士沒有購買TG Therapeutics的股票,但出現了一些拋售。在過去的一年裏,沒有任何能讓我們感到安慰的購買。該公司擁有很高的內部所有權,但考慮到股票銷售的歷史,我們有點猶豫。除了了解正在進行的內幕交易外,確定TG Therapeutics面臨的風險也是有益的。每家公司都有風險,我們發現了一個你應該知道的TG Therapeutics警告信號。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件給編輯組(網址爲)simplywallst.com。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論